1. Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis
   Xin Liu et al, 2018, Investigational New Drugs CrossRef
2. A Novel Nanoemulsion Formula for an Improved Delivery of a Thalidomide Analogue to Triple-Negative Breast Cancer; Synthesis, Formulation, Characterization and Molecular Studies
   Noran M Tawfik et al, 2023, International Journal of Nanomedicine CrossRef
3. Construction of a circRNA-miRNA-mRNA Regulatory Network Reveals Potential Mechanism and Treatment Options for Osteosarcoma
   Yi He et al, 2021, Frontiers in Genetics CrossRef
4. Synergistic effects of thalidomide and cisplatin are mediated via the PI3K/AKT and JAK1/STAT3 signaling pathways in cervical cancer
   Cairu Liu et al, 2022, Oncology Reports CrossRef
5. Towards understanding the interaction of (S)-thalidomide with nucleobases
   Angelika Baranowska-Łączkowska et al, 2020, Archives of Biochemistry and Biophysics CrossRef
6. Combination of Mitochondrial and Plasma Membrane Citrate Transporter Inhibitors Inhibits De Novo Lipogenesis Pathway and Triggers Apoptosis in Hepatocellular Carcinoma Cells
   Wan-angkan Poolsri et al, 2018, BioMed Research International CrossRef
7. Complexity‐to‐Diversity and Pseudo‐Natural Product Strategies as Powerful Platforms for Deciphering Next‐Generation Therapeutics
   Bilal O. Alkubaisi et al, 2023, ChemMedChem CrossRef
8. Anti-cancer targets and molecular mechanisms of formononetin in treating osteosarcoma based on network pharmacology
   Lizhi Chen et al, 2023, Aging CrossRef